Fundz Deep Dive
Everything you need to win Gilad Mamlok — in one platform.
Who to reach, what to say, and why now on Gilad Mamlok — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Gilad Mamlok — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Protalix Bio Therapeutics Appoints Gilad Mamlok As Chief Financial Officer
PUBLIC · PLXJul 21, 2025•11 months ago
Position
Chief Financial Officer
Company
Protalix BioTherapeutics
KarmielManufacturingBiotechnologyTherapeuticsBiopharmaDescription
Protalix BioTherapeutics has appointed Gilad Mamlok as the new Chief Financial Officer, effective August 24, 2025. He succeeds Eyal Rubin, who will assist during the transition period until October 2025.
Executive Insights
Based on hiring dataNew executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months